Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

Aytu BioPharma, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

DENVER, CO / ACCESS NEWSWIRE / DECEMBER 18, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, WILL BE HOSTING AN INVESTOR DAY ON TUESDAY, JANUARY 20, 2026, AT 11:00 A.M. EASTERN TIME IN NEW YORK CITY.

AYTU BIOPHARMA TO HOST INVESTOR DAY ON JANUARY 20, 2026 IN NEW YORK CITY

EXXUA IS NOW AVAILABLE THROUGH AYTU RXCONNECT PHARMACIES TO ENSURE OPTIMAL ACCESS AND AVAILABILITY EXXUA HAS DEMONSTRATED SIGNIFICANT IMPROVEMENT IN DEPRESSION SYMPTOMS IN CLINICAL TRIALS INVOLVING MORE THAN 5,000 PATIENTS AND, NOTABLY, HAS NO WARNINGS OR ADVERSE EVENTS RELATED TO SEXUAL DYSFUNCTION AND NO CLINICALLY SIGNIFICANT WEIGHT GAIN COMPARED TO PLACEBO DENVER, CO / ACCESS NEWSWIRE / DECEMBER 15, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED THE COMMERCIAL AVAILABILITY OF EXXUA IN THE UNITED STATES. EXXUA IS THE FIRST AND ONLY 5HT1A AGONIST APPROVED BY THE UNITED STATES FOOD AND DRUG ADMINISTRATION FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER ("MDD"), REPRESENTING A NEW WAY TO TREAT MDD.

AYTU BIOPHARMA ANNOUNCES COMMERCIAL AVAILABILITY OF EXXUA(TM) (GEPIRONE) EXTENDED-RELEASE TABLETS, THE FIRST AND ONLY 5HT1A AGONIST INDICATED FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER IN ADULTS

DENVER, CO / ACCESS NEWSWIRE / NOVEMBER 24, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED THAT ITS MANAGEMENT WILL PARTICIPATE AT NOBLECON21 - NOBLE CAPITAL MARKETS' 21ST ANNUAL EMERGING GROWTH EQUITY CONFERENCE AT FLORIDA ATLANTIC UNIVERSITY, EXECUTIVE EDUCATION COMPLEX, IN BOCA RATON, FL. MANAGEMENT WILL BE PRESENTING ON WEDNESDAY, DECEMBER 3RD AT 10:30 A.M.

AYTU BIOPHARMA TO PARTICIPATE IN NOBLE CAPITAL MARKETS 21ST ANNUAL EMERGING GROWTH EQUITY CONFERENCE

TOTAL NET REVENUE OF $13.9 MILLION NET INCOME OF $2.0 MILLION, OR $0.21 NET INCOME PER SHARE BASIC ADJUSTED EBITDA1 OF $(0.6) MILLION, WHICH INCLUDES EXXUA LAUNCH INVESTMENTS $32.6 MILLION CASH BALANCE AT SEPTEMBER 30, 2025 COMPANY REMAINS ON TRACK TO LAUNCH EXXUA  (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA " ) IN THE FOURTH CALENDAR QUARTER OF 2025 AS A CENTERPIECE OF ITS COMMERCIAL EFFORTS AS IT ENTERS THE OVER $22 BILLION UNITED STATES PRESCRIPTION MAJOR DEPRESSIVE DISORDER ("MDD") MARKET COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, NOVEMBER 13, 2025, AT 4:30 P.M. EASTERN TIME DENVER, CO / ACCESS NEWSWIRE / NOVEMBER 13, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED OPERATIONAL AND FINANCIAL RESULTS FOR THE FISCAL 2026 FIRST QUARTER.

AYTU BIOPHARMA REPORTS FISCAL 2026 FIRST QUARTER OPERATIONAL AND FINANCIAL RESULTS

DENVER, CO / ACCESS NEWSWIRE / NOVEMBER 5, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, WILL REPORT ITS OPERATIONAL AND FINANCIAL RESULTS FOR ITS FIRST QUARTER OF FISCAL 2026, AFTER THE MARKET CLOSE ON THURSDAY, NOVEMBER 13, 2025. THE COMPANY HAS SCHEDULED A CONFERENCE CALL AND WEBCAST THAT SAME DAY, THURSDAY, NOVEMBER 13, 2025, AT 4:30 P.M.

AYTU BIOPHARMA TO REPORT FISCAL 2026 FIRST QUARTER OPERATIONAL AND FINANCIAL RESULTS ON NOVEMBER 13, 2025

DENVER, CO / ACCESS NEWSWIRE / OCTOBER 28, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED THAT THE METHOD OF USE PATENT (U.S. PATENT NO. 7,538,116) FOR EXXUATM (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA") HAS BEEN EXTENDED THROUGH SEPTEMBER 2, 2030 UNDER 35 U.S.C.

AYTU BIOPHARMA ANNOUNCES PATENT TERM EXTENSION FOR EXXUA(TM)

DENVER, CO / ACCESS NEWSWIRE / OCTOBER 10, 2025 /AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES: 2025 MAXIM GROWTH SUMMIT DATE: OCTOBER 22, 2025 LOCATION: NEW YORK CITY INVESTORS SHOULD REACH OUT TO THEIR MAXIM SALES REPRESENTATIVES, OR ROBERT BLUM OF LYTHAM PARTNERS AT AYTU@LYTHAMPARTNERS.COM TO SCHEDULE ONE-ON-ONE MEETINGS WITH AYTU'S MANAGEMENT. PLANET MICROCAP SHOWCASE: TORONTO 2025 DATE: OCTOBER 22, 2025 - OCTOBER 23, 2025 LOCATION: TORONTO PRESENTATION TIME: 2:30 P.M.

AYTU BIOPHARMA TO PRESENT AT UPCOMING OCTOBER 2025 CONFERENCES

DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 24, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED MANAGEMENT WILL PARTICIPATE AT THE FOLLOWING INVESTOR CONFERENCES: MICROCAP RODEO FALL CONFERENCE DATE: THURSDAY, SEPTEMBER 25, 2025 LOCATION: NEW YORK CITY PRESENTATION TIME: 2:00 P.M. EASTERN TIME WEBCAST: HTTPS://WWW.WEBCASTER5.COM/WEBCAST/PAGE/3142/53024 LYTHAM PARTNERS FALL 2025 INVESTOR CONFERENCE DATE: TUESDAY, SEPTEMBER 30, 2025 LOCATION: VIRTUAL PRESENTATION TIME: 2:45 P.M.

AYTU BIOPHARMA TO PRESENT AT UPCOMING SEPTEMBER 2025 CONFERENCES

FULL YEAR FISCAL 2025 NET REVENUE OF $66.4 MILLION FULL YEAR FISCAL 2025 NET LOSS OF $13.6 MILLION FULL YEAR FISCAL 2025 ADJUSTED EBITDA1 OF $9.2 MILLION $31.0 MILLION CASH BALANCE AT JUNE 30, 2025 EXCLUSIVE AGREEMENT IN JUNE 2025 TO COMMERCIALIZE EXXUA (GEPIRONE) EXTENDED-RELEASE TABLETS ("EXXUA") IS EXPECTED TO SERVE AS A MAJOR GROWTH CATALYST; THE COMPANY ANTICIPATES LAUNCHING EXXUA IN THE FOURTH CALENDAR QUARTER OF 2025 AS A CENTERPIECE OF ITS COMMERCIAL EFFORTS AS IT ENTERS THE OVER $22 BILLION UNITED STATES PRESCRIPTION MAJOR DEPRESSIVE DISORDER ("MDD") MARKET WITH WHAT THE COMPANY BELIEVES TO BE A NOVEL FIRST-IN-CLASS ORAL SELECTIVE SEROTONIN 5HT1A RECEPTOR AGONIST FOR ADULTS WITH MDD COMPANY TO HOST CONFERENCE CALL AND WEBCAST TODAY, SEPTEMBER 23, 2025, AT 4:30 P.M. EASTERN TIME DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 23, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, TODAY ANNOUNCED OPERATIONAL AND FINANCIAL RESULTS FOR THE FISCAL 2025 FULL YEAR AND FOURTH QUARTER.

AYTU BIOPHARMA REPORTS FISCAL 2025 FULL YEAR AND FOURTH QUARTER OPERATIONAL AND FINANCIAL RESULTS AND OUTLINES COMMERCIAL LAUNCH PLANS FOR EXXUA(TM)

DENVER, CO / ACCESS NEWSWIRE / SEPTEMBER 16, 2025 / AYTU BIOPHARMA, INC. (THE "COMPANY" OR "AYTU") (NASDAQ:AYTU), A PHARMACEUTICAL COMPANY FOCUSED ON ADVANCING INNOVATIVE MEDICINES FOR COMPLEX CENTRAL NERVOUS SYSTEM DISEASES TO IMPROVE THE QUALITY OF LIFE FOR PATIENTS, WILL REPORT ITS OPERATIONAL AND FINANCIAL RESULTS FOR ITS FISCAL 2025 FULL YEAR AND FOURTH QUARTER, AFTER THE MARKET CLOSE ON TUESDAY, SEPTEMBER 23, 2025. THE COMPANY HAS SCHEDULED A CONFERENCE CALL AND WEBCAST THAT SAME DAY, TUESDAY, SEPTEMBER 23, 2025, AT 4:30 P.M.

Aytu BioPharma, Inc.

AYTU

Price

Financial Reports

No items found.

Press Releases

Aytu BioPharma, Inc.

AYTU.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

AYTU